Media stories about Pfizer (NYSE:PFE) have been trending somewhat negative on Wednesday, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pfizer earned a media sentiment score of -0.07 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.1373018989409 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Pfizer Inc (NYSE:PFE) Heffx Technical Analysis – Live Trading News (livetradingnews.com)
- Pfizer (PFE) Says Updated Data from Phase 3 Trial of IBRANCE Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in PFS (streetinsider.com)
- Frayed Gasket Delaying Astra’s ZS-9 Shows Pharma M&A Perils (finance.yahoo.com)
- Pfizer Inc. breached its 50 day moving average in a Bearish Manner : PFE-US : December 6, 2017 (finance.yahoo.com)
- UBS Reiterates “$40.00” Price Target for Pfizer (PFE) (americanbankingnews.com)
Several equities analysts recently issued reports on PFE shares. Cowen set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Monday, August 14th. BMO Capital Markets set a $37.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, October 10th. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research report on Tuesday, October 3rd. Finally, Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, September 19th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $38.77.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter last year, the business posted $0.61 EPS. The business’s revenue was up .9% on a year-over-year basis. equities analysts forecast that Pfizer will post 2.59 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Shareholders of record on Friday, November 10th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.59%. The ex-dividend date of this dividend was Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is currently 78.53%.
In other news, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the transaction, the insider now owns 145,649 shares in the company, valued at approximately $5,097,715. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the transaction, the executive vice president now owns 117,432 shares of the company’s stock, valued at approximately $4,186,450.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,280 shares of company stock valued at $2,118,988. Company insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.